GO
Loading...

Bristol-Myers Squibb Co

More

  • Oct 1- Portola Pharmaceuticals Inc said its drug met the main goal of reversing the effect of anti-coagulant drugs in a late-stage study. Data showed that an intravenous shot of the drug, andexanet alfa, immediately reversed the effect of Eliquis, an anti-clotting drug by Bristol-Myers Squibb Co and Pfizer Inc..

  • MADRID, Sept 30- A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects-- but their high cost is a growing concern. Price-- just as much as safety and efficacy-- has proved a hot topic for nearly 20,000 oncology experts at the European Society for Medical Oncology annual congress in Madrid.

  • Cancer drug stocks on the move amid striking data Monday, 29 Sep 2014 | 11:14 AM ET

    Data released at the European Society of Medical Oncology meeting over the weekend showed much progress in fighting a number of cancers. Here's what investors need to know.

  • MADRID, Sept 28- Merck& Co's drug Keytruda, the first in a new wave of immune-boosting medicines to be approved for treating melanomas in the United States, also has potential in stomach cancer, new research shows.

  • *AstraZeneca says tolerability profile encouraging. MADRID, Sept 27- Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system show the cocktail is promising, though limited patient numbers mean the data is far from conclusive.

  • *AstraZeneca says tolerability profile encouraging. MADRID, Sept 27- Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system suggest the cocktail is promising, though limited patient numbers mean the data is far from conclusive.

  • Cramer's Remix: Selloff strategies to survive drop Thursday, 25 Sep 2014 | 6:57 PM ET

    Upset by the spiral lower? Cramer feels your pain. And he’s developed strategies for surviving circumstances just like these.

  • Cramer’s Bristol-Myers theorem: What is it? Thursday, 25 Sep 2014 | 6:28 PM ET

    You always hear Cramer shouting about Bristol – Maaah-yerss. Why is that?

  • PARIS, Sept 18- French cancer immunotherapy specialist OSE Pharma has registered with market regulator AMF for an initial public offering aimed at financing late-stage trials of its Texopi drug for the most common form of lung cancer, the company said on Thursday.

  • Can anything slow Gilead down? Analysts say no Monday, 8 Sep 2014 | 3:12 PM ET
    Darryl Kato, research scientist for Gilead Sciences, works on the synthesis of a potential hepatitis C virus drug candidate at the company's lab in Foster City, California, Feb. 8, 2012.

    Gilead is already among the 10 best performers in the Nasdaq 100 this year. So can anything slow this behemoth down? If you ask the analysts, it sounds unlikely.

  • *Novartis's LCZ696 and PCSK9 drugs could treat millions. Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies.

  • *AstraZeneca shares up 2 percent. LONDON, Aug 29- Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.

  • Early movers: TIF, AAPL, T, AGN, PFE, TIVO & more Wednesday, 27 Aug 2014 | 8:13 AM ET
    Traders work on the floor of the New York Stock Exchange (NYSE) on Friday.

    Some of the names on the move ahead of the open.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • There's still hunger for 'blockbuster' biotech deals Monday, 25 Aug 2014 | 10:58 AM ET
    Severin Schwan, chief executive officer Roche Holding.

    Roche's deal for InterMune is one of the few this year that returns to the traditional model of big pharma buying smaller biotech.

  • LOS ANGELES, Aug 25- U.S. regulators are likely to approve Merck& Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

  • Midday movers: Apple, Macy's, Shutterfly & more Wednesday, 20 Aug 2014 | 1:18 PM ET

    Some of Wednesday's midday movers:

  • Diversified U.S. manufacturer 3 M Co and medical equipment makers CareFusion Corp and C.R. Bard Inc are among the companies exploring a potential deal for ConvaTec, the people said. CareFusion, with a market capitalization of $9 billion, and C.R. Bard, with $11.2 billion, would both be able to achieve an inversion if they use their own stock to pay for ConvaTec.

  • The R&D elite: America's most innovative companies Wednesday, 6 Aug 2014 | 6:00 AM ET

    The CNBC RQ 50 identifies companies that don't just spend big on R&D, but spend right, creating return on innovation for shareholders.

  • Why dying kids can't get the drugs they need Tuesday, 5 Aug 2014 | 7:33 AM ET
    Nathalie Traller back in the clinic.

    Terminally ill patients are increasingly seeking access experimental drugs outside clinical trials, but drug companies often decline these requests. A look at why.